Dianthus Therapeutics, Inc.
DNTH
$20.00
$0.050.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 120.63% | 51.41% | 8.57% | -46.52% | -55.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 120.63% | 51.41% | 8.57% | -46.52% | -55.96% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 120.63% | 51.41% | 8.57% | -46.52% | -55.96% |
| SG&A Expenses | 37.64% | 46.47% | 176.15% | 163.58% | 169.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 111.96% | 78.49% | 72.71% | 59.88% | 41.19% |
| Operating Income | -111.45% | -80.58% | -79.04% | -79.62% | -62.17% |
| Income Before Tax | -95.08% | -55.64% | -56.89% | -63.65% | -52.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.08% | -55.64% | -56.89% | -63.65% | -52.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.08% | -55.64% | -56.89% | -63.65% | -52.95% |
| EBIT | -111.45% | -80.58% | -79.04% | -79.62% | -62.17% |
| EBITDA | -111.55% | -80.61% | -79.05% | -79.62% | -62.11% |
| EPS Basic | 89.75% | 93.10% | 86.58% | 40.79% | -9.61% |
| Normalized Basic EPS | 89.73% | 93.07% | 86.58% | 40.79% | -9.61% |
| EPS Diluted | 89.75% | 93.10% | 86.58% | 40.79% | -9.61% |
| Normalized Diluted EPS | 89.73% | 93.07% | 86.58% | 40.79% | -9.61% |
| Average Basic Shares Outstanding | 530.86% | 1,568.15% | 2,147.23% | 582.49% | 109.66% |
| Average Diluted Shares Outstanding | 530.86% | 1,568.15% | 2,147.23% | 582.49% | 109.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |